Glaucoma Patents (Class 514/913)
  • Patent number: 6716830
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: April 6, 2004
    Assignee: Alcon, Inc.
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
  • Patent number: 6673812
    Abstract: An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I) wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided. The agent for the prophylaxis and treatment of glaucoma of the present invention is a novel agent for the prophylaxis and treatment of glaucoma and has intraocular pressure lowering action, optic disc blood flow improving action and aqueous humor outflow promoting action.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: January 6, 2004
    Assignees: Senju Pharmaceutical Co., Ltd., Mitsubishi Pharma Corporation
    Inventors: Mitsuyoshi Azuma, Yukuo Yoshida, Mitsunori Waki, Masayoshi Uehata
  • Patent number: 6664286
    Abstract: Compounds with 5HT2 receptor agonist activity useful for treating glaucoma, including lowering intraocular pressure. Compositions and methods for their use are also disclosed.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: December 16, 2003
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Jesse A. May, Thomas R. Dean, Najam A. Sharif, Mark R. Hellberg
  • Patent number: 6649195
    Abstract: A powerful formulation for preventing and treating macular degeneration, cataracts, glaucoma and other eye diseases, and contains over thirty naturally effective vitamins, minerals, phytonutrients and amino acids, which have all been found to demonstrate a powerful protective effect on the health of the eye.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: November 18, 2003
    Assignee: Vitacost.com, Inc.
    Inventor: Wayne F. Gorsek
  • Patent number: 6646001
    Abstract: Disclosed are methods and compositions for the treatment of glaucoma and ocular hypertension, comprising the administration of a prostaglandin FP receptor agonist and a prostaglandin synthesis inhibitor.
    Type: Grant
    Filed: January 28, 2002
    Date of Patent: November 11, 2003
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Mark R. Hellberg, Jon C. Nixon
  • Patent number: 6627603
    Abstract: A method for the controlled release of an active principle contained in a multiple water-in-oil-in-water emulsion characterized in that the multiple emulsion comprises an invert emulsion Ei with an aqueous phase A1 containing at least a hydrophilic active principle. The emulsion Ei is dispersed in the form of direct emulsion droplets Ed, in a continuous aqueous phase A2, with the two emulsions Ed and Ei stabilized by at least a surfactant, present in their respective continuous phases. The multiple emulsion is brought in the presence of an effective amount of an agent for transforming it into a direct emulsion and induce the release of the active principle, contained in the aqueous phase A1 of emulsion Ei, in the aqueous phase A2.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: September 30, 2003
    Assignee: Centre National de la Recherche Scientifiquue (C.N.R.S.)
    Inventors: Jérôme Bibette, Marie-Françoise Ficheux, Fernando Leal Calderon, Lida Bonnakdar
  • Patent number: 6596765
    Abstract: 15-keto latanoprost and other 15-keto prostaglandin analogs are used as ocularly applied intraocular pressure reducing agents.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: July 22, 2003
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 6586425
    Abstract: Methods for the treatment of glaucoma are provided by the present invention. The compounds described cause a perturbation of the actin cytoskeleton in the trabecular meshwork or the modulation of its interactions with the underlying membrane. Perturbation of the cytoskeleton and the associated adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
    Type: Grant
    Filed: January 29, 2001
    Date of Patent: July 1, 2003
    Assignees: Wisconsin Alumni Research Foundation, Yeda Research and Development Co., Ltd.
    Inventors: Paul L. Kaufman, Benjamin Geiger
  • Patent number: 6565894
    Abstract: An ophthalmic solution comprising: 0.01 to 5 weight percent imidazole: 0.01 to 30 weight percent hydrogen peroxide and the balance water which can further comprisie 0.01 to 2 weight percent of a buffer adjusted so the pH of the formulation is between 5.5 to 8.5.
    Type: Grant
    Filed: November 4, 2000
    Date of Patent: May 20, 2003
    Inventors: Francis X. Smith, John Randall Tracey
  • Patent number: 6555582
    Abstract: The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: April 29, 2003
    Assignee: The Regents of the University of California
    Inventors: Daniel M. Schwartz, John D. Baxter, Michele D. Jumper, Thomas S. Scanlan
  • Patent number: 6548535
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 15, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • Patent number: 6545045
    Abstract: This application relates to compositions and methods for the treatment of glaucoma and/or ocular hypertension in mammals utilizing prostaglandin E receptor agonists.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: April 8, 2003
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Peter G. Klimko, Najam A. Sharif, Brenda W. Griffin
  • Patent number: 6545036
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Gregory J. Kaczorowski, Owen B. McManus
  • Patent number: 6534475
    Abstract: Methods and compositions for treating ocular neovascularization with TIMP-3, TIMP-3 inducers, and TIMP-3 mimetics are disclosed.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: March 18, 2003
    Assignee: Alcon, Inc.
    Inventor: Abbot F. Clark
  • Patent number: 6528516
    Abstract: This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: March 4, 2003
    Assignee: Trustees of the University of Pennsylvania, The Center for Technology Transfer
    Inventors: Mortimer M. Civan, Richard A. Stone, Claire H. Mitchell, Kenneth A. Jacobson
  • Patent number: 6511660
    Abstract: The present invention provides novel ophthalmic drug delivery formulation which comprises a mixture of Carbopol and Pluronic. Carbopol is a trademark of B.F. Goodrich Company's high molecular weight carboxy vinyl polymers (MW above 1,000,000). Pluronic belongs to a class of block copolymers containing polyoxyethylene and polyoxypropylene. The preferred weight percentages of Carbopol and Pluronic in the ophthalmic drug delivery formulation are 0.3% of Carbopol and 14% of Pluronic. The ocular bioavailability is greatly enhanced by the use of the ophthalmic drug delivery formulation of the present invention.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: January 28, 2003
    Inventors: Hong-Ru Lin, Kuo-Chun Sung
  • Patent number: 6509332
    Abstract: This invention comprises methods of treatment, prevention, inhibition or alleviation of the problems associated with excessive intraocular pressure comprising administration of a compound of the formulae I or II: wherein Z is a moiety selected from the group of: wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH; Y is the moiety: R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: January 21, 2003
    Assignee: Wyeth
    Inventor: Simon Nicholas Jenkins
  • Patent number: 6500831
    Abstract: This invention relates to the topical ocular use of non-peptide bradykinin receptor antagonists to treat glaucoma and ocular hypertension.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: December 31, 2002
    Assignee: Alcon Manufacturing, Ltd.
    Inventor: Najam A. Sharif
  • Patent number: 6458836
    Abstract: Disclosed is treatment of ocular hypertension and glaucoma by long-term therapy with a prostaglandin related compound for eliminating or reducing potential iridic pigmentation. Composition useful for the treatment, and use of the prostaglandin related compound for producing the composition are also disclosed.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: October 1, 2002
    Assignee: Sucampo, A.G.
    Inventor: Ryuji Ueno
  • Patent number: 6458376
    Abstract: Nonaqueous pharmaceutical compositions for use in aqueous physiological systems are disclosed comprising drug delivery suspension of nonaqueous perfluorocarbon or fluorinated silicone liquid carriers. The suspended drug may be water labile or water stable and therapeutic or diagnostic compounds which will remain stable and pharmaceutically effective for extended periods. The pharmaceutical compositions have improved bioavailability, are capable of low dose volume delivery, and do not degrade the incorporated therapeutic or diagnostic compounds making them well suited for multi-dose packaging and administration.
    Type: Grant
    Filed: December 30, 1993
    Date of Patent: October 1, 2002
    Assignee: Allergan, Inc.
    Inventor: David Louis Meadows
  • Patent number: 6455590
    Abstract: Methods and kits for treament of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: September 24, 2002
    Assignee: University of Toronto Innovations.Foundation
    Inventor: William G. Tatton
  • Patent number: 6451799
    Abstract: An agent for ameliorating ocular circulatory disorder containing a 1,4-dihydropyridine derivative of the formula (I) wherein each symbol is as defined in the specification, or an acid addition salt thereof as an active ingredient. The agent for ameliorating ocular circulatory disorder containing the compound of the above formula (I) increases optic disc blood flow of normal eye particularly by instillation, and inhibits vasocontraction of retinal blood vessel, decrease in optic disc blood flow and attenuation of the amplitude of VEP caused by ET-1, without increasing the intraocular pressure.
    Type: Grant
    Filed: April 27, 1999
    Date of Patent: September 17, 2002
    Assignees: Senju Pharmaceutical Co., Ltd., Kyoto Pharmaceutical Industries, Ltd.
    Inventors: Takahiro Ogawa, Noriko Watanabe, Mitsunori Waki
  • Patent number: 6448378
    Abstract: Disclosed herein are collagen films which rapidly dissolve at 35° C. Also disclosed are methods for the preparation of the collagen films and their use as a vehicle for delivering a dose of therapeutic compound to a specific tissue site.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: September 10, 2002
    Inventors: Dale P. DeVore, Richard A. Eiferman, Edwin U. Keates
  • Patent number: 6444676
    Abstract: The invention provides pharmaceutical compositions containing PARP inhibitors and methods of using these compositions to prevent, treat or ameliorate glaucomatous retinopathy and/or optic neuropathy.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 3, 2002
    Inventors: Iok-Hou Pang, Abbot F. Clark
  • Patent number: 6441047
    Abstract: Methods for treating persons with glaucoma or ocular hypertension with glutamate antagonists and IOP-lowering compounds are disclosed.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: August 27, 2002
    Assignee: Alcon Manufacturing Ltd..
    Inventor: Louis DeSantis, Jr.
  • Patent number: 6426358
    Abstract: A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na+ via non-inactivating Na+ chanels, and the lethal elevation of cell Ca2+ due to reversal of the Na+/Ca2+ exchanger. The method includes blocking, by administration of a selected composition, of associated, non-inactivating Na+ channels in retinal ganglion cells in order to limit Na+/Ca+ exchange in the retinal ganglion cells and prevent buildup of the Ca2+ level in the retinal ganglion cells to a lethal level. The results in a method of preventing retinal ganglion cell death, associated with glaucoma, by administering to the optic nerve of a mammal, a compound which blocks the non-inactivating sodium ion channels of the optic nerve.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: July 30, 2002
    Assignee: Allergan Sales, Inc.
    Inventor: Joseph S. Adorante
  • Patent number: 6423321
    Abstract: Specific Cytokine Antagonists, including TNF antagonists and/or Interleukin-1 antagonists, are used as novel therapeutic agents for the treatment of hearing loss, including presbycusis and other forms of sensorineural hearing loss. The present invention provides a method for inhibiting the action of TNF and/or IL-1 antagonists for treating hearing loss in a human by administering a TNF antagonist and/or an IL-1 antagonist for reducing the inflammation affecting the auditory apparatus of said human, or for modulating the immune response affecting the auditory apparatus of said human, by administering a therapeutically effective dosage level to said human of a TNF antagonist and/or an IL-1 antagonist. Administration may be systemic, through the subcutaneous, intramuscular, oral, or intravenous routes; or by delivering an anatomically localized application in the region of the head.
    Type: Grant
    Filed: December 27, 2000
    Date of Patent: July 23, 2002
    Inventor: Edward L. Tobinick
  • Patent number: 6419944
    Abstract: Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor; interleukin-1; interleukin-6; and interleukin-8.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: July 16, 2002
    Inventor: Edward L. Tobinick
  • Patent number: 6414021
    Abstract: An ocular infusion solution containing a prostaglandin-like compound or prostaglandin-analog is used during ocular surgery for maintaining desired intraocular pressure of the patient.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: July 2, 2002
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 6403590
    Abstract: Isoquinolinesulfonyl compounds are used in ophthalmic compositions to treat glaucoma or other ischemic-borne ocular disorders such as retinopathies or optic neuropathies. These compounds vasodilate ocular blood vessels, lower IOP and prevent or reduce the progression of visual field loss.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: June 11, 2002
    Assignee: Alcon Laboratories, Inc.
    Inventors: Mark R. Hellberg, Michael A. Kapin, Louis M. Desantis, Jr.
  • Patent number: 6395932
    Abstract: The present invention provides compounds represented by the following formula [I] or salts thereof which lower intraocular pressure by causing morphological change in trabecular meshwork cells. In the formula, R1 is H, lower alkyl, hydroxy, lower alkoxy or halogen, R2, R3 and R4 are H or lower alkyl, and . . . is a single bond or a double bond. When R3 and/or R4 is hydrogen, the amino can be protected by a protecting group.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: May 28, 2002
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Eiichi Shirasawa, Masaki Ichikawa, Hiroshi Suhara
  • Patent number: 6387889
    Abstract: Medicinal compositions for treating eye diseases which contain as the active ingredient 2-alkynyladenosine derivatives having an acetylene union at the 2-position of adenine base. Having a long-lasting and remarkable effect of lowering ocular tension, these compositions are useful as remedies for eye diseases accompanying increased ocular tension or optic nerve failures, such as glaucoma and hypertonia oculi.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: May 14, 2002
    Assignees: Yamasa Corporation, Toa Eiyo Ltd.
    Inventors: Kazuki Endo, Toichi Abiru, Tomokazu Hosokawa, Miwa Misawa, Takashi Konno
  • Patent number: 6387910
    Abstract: A novel drug for improving the circulation in the optic nerve head, which comprises as an active ingredient Lomerizine (I): or a pharmaceutically acceptable acid addition salt. The optic nerve head circulation improving drug of this invention can increase the blood flow in the optic nerve head with no or little systemic side effects such as hypotensive activity or heart rate increasing activity and is useful particularly for the treatment of normal tension glaucoma.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: May 14, 2002
    Assignee: Akzo Nobel N.V.
    Inventors: Hideaki Hara, Masamitsu Shimazawa, Yasushi Iwakura, Tetsuya Sugiyama
  • Patent number: 6384073
    Abstract: Macrolide compounds, such as the FK506 Substance and its related compounds, are provided for the prevention or treatment of eye diseases, particularly glaucoma. Composition containing such compounds is also disclosed.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: May 7, 2002
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventor: Shozo Sakuma
  • Patent number: 6376541
    Abstract: A method of lowering intraocular pressure (IOP) employs an upregulating agent that induces increased prostaglandin synthesis in the eye. The method of treatment entails administering to the eye of a mammal in need thereof a prostaglandin upregulating agent to increase endogenous prostaglandin synthesis and thereby effect a reduction in intraocular pressure. In a preferred embodiment the upregulating agent is IL-1.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: April 23, 2002
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Jon C. Nixon, Karen C. David
  • Patent number: 6369116
    Abstract: Implants and methods are provided for modulating wound healing and controlling infection to improve the success of glaucoma filtration surgery. Formulations of one or more therapeutically active agents and a biodegradable polymer provide a substantially constant rate of release for an extended period of time.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: April 9, 2002
    Assignee: Oculex Pharmaceuticals, Inc.
    Inventors: Vernon Wong, Lin Peng
  • Patent number: 6359001
    Abstract: The use of agents for blocking the synthesis of tyrosinase to prevent permanent pigmentation of the iris caused by melanin deposit induced by pharmacological treatments or by metabolic imbalance is described.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: March 19, 2002
    Assignee: Pharmacia AB
    Inventor: Filippo Drago
  • Patent number: 6350467
    Abstract: A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: February 26, 2002
    Assignee: Antioxidant Pharmaceuticals Corp.
    Inventors: Harry B. Demopoulos, Myron L. Seligman
  • Patent number: 6344485
    Abstract: Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: February 5, 2002
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Bruce A. Lefker
  • Patent number: 6342524
    Abstract: Disclosed are methods and compositions for the treatment of glaucoma and ocular hypertension, comprising the administration of a prostaglandin analog and a prostaglandin synthesis inhibitor.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: January 29, 2002
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Mark R. Hellberg, Jon C. Nixon
  • Patent number: 6331523
    Abstract: The present invention relates to the use of FGF-5 polypeptides to delay, prevent or rescue retinal neurons, including photoreceptors, other retinal cells or supportive cells (e.g. Müller cells or RPE cells) from injury and degradation. Conditions comprehended by treatment of the present FGF-5 polypeptides (including variants), antibodies, compositions and articles of manufacture include: retinal detachment, age-related and other maculopathies, photic retinopathies, surgery-induced retinopathies (either mechanically or light-induced), toxic retinopathies including those resulting from foreign bodies in the eye, diabetic retinopathies, retinopathy of prematurity, viral retinopathies such as CMV or HIV retinopathy related to AIDS, uveitis, ischemic retinopathies due to venous or arterial occlusion or other vascular disorder, retinopathies due to trauma or penetrating lesions of the eye, peripheral vitreoretinopathy, and inherited retinal degenerations. Exemplary retinal degenerations include e.g.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: December 18, 2001
    Assignee: Genentech, Inc.
    Inventors: Ivar J. Kljavin, Monique La Fleur
  • Patent number: 6329426
    Abstract: By combined administration of a non-FP receptor agonist type prostaglandin compound, for example isopropyl unoprostone, and a FP-receptor type prostaglandin compound, for example Latanoprost, the ocular hypotensive effect of the prostaglandin compounds is enhanced synergistically.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: December 11, 2001
    Assignee: R-Tech Ueno, Ltd.
    Inventor: Ryuji Ueno
  • Patent number: 6329369
    Abstract: Methods of treating glaucoma or elevated pressure and other diseases with reduced side effects by treating a mammal in need thereof an agonist of the alpha 2B or alpha 2B/2C adrenergic receptor(s). Also described are compounds having such selective agonist activity.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: December 11, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Ken Chow, Daniel W. Gil, James A. Burke, Dale A. Harcourt, Michael E. Garst, Larry A. Wheeler, Stephen A. Munk
  • Patent number: 6316441
    Abstract: Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: November 13, 2001
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Thomas R. Dean, Louis Desantis, Jr., Billie M. York
  • Patent number: 6316443
    Abstract: Combinations of a &bgr;-adrenergic antagonist and a topical carbonic anhydrase inhibitor are particularly useful in the treatment of ocular hypertension, especially in patients insufficiently responsive to treatment with &bgr;-adrenergic antagonists.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: November 13, 2001
    Assignee: Merck & Co., Inc.
    Inventor: John J. Baldwin
  • Patent number: 6300328
    Abstract: Selective AMPDA inhibitors for preventing and treating damage to the optic nerve and/or retina are disclosed.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: October 9, 2001
    Assignee: Alcon Universal Ltd.
    Inventor: Peter G. Klimko
  • Patent number: 6297240
    Abstract: This invention relates to pharmaceutical compositions for oral administration comprising a carrier and, as active ingredient, an ophthalmologically active compound, characterized in that the composition is formulated to promote pre-gastric absorption of the ophthalmologically active compound. A process for preparing such compositions and the use of such compositions for the treatment of ophthalmic diseases, particularly diseases caused by elevated intro-ocular pressure, such as ocular hypertension and glaucoma, are also provided.
    Type: Grant
    Filed: February 8, 1999
    Date of Patent: October 2, 2001
    Assignee: R.P. Scherer Limited
    Inventor: Jonathan Kenneth Embleton
  • Patent number: 6294563
    Abstract: The invention concerns combinations of alpha adrenergic agents such as brimonidine and its derivatives as represented by formula (I) below wherein each Y is independently selected from the group consisting of N, N—CH3, O, S and C—R1; R1 is hydrogen, lower alkyl or oxo; R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, lower alkyl and lower alkenyl; n is an integer from 1 to 3; and a broken line beside a solid line indicates either a single or a double bond with the proviso that when n=1, both bonds from Y to C—R1 cannot be double bonds, and prostaglandins known in the art to cause lowering of intraocular pressure which are useful in compositions, methods of treatment and articles of manufacture for the treatment of glaucoma and alleviation of elevated intraocular pressure and providing neuroprotection.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: September 25, 2001
    Assignee: Allergan Sales, Inc.
    Inventor: Michael E. Garst
  • Patent number: 6291506
    Abstract: Disclosed is a method of reducing intraocular pressure or retinal ganglion cell death caused by specific reactive oxygen species by delivering carvedilol or a derivative or metabolite thereof having beta-adrenergic antagonist activity or specific reactive oxygen species scavenging activity to the retinal ganglion cells of a subject having or at risk of developing glaucomatous or other optic neuropathy.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: September 18, 2001
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Leonard A Levin
  • Patent number: 6291529
    Abstract: Compounds characterized generally as alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol derivatives are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are those of Formula II: wherein q is two or three; wherein r is zero or two; wherein R2 is selected from hydrido, methyl, ethyl and phenyl; wherein R3 is selected from hydrido, cyclohexylmethyl, benzyl, fluorobenzyl, chlorobenzyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein R5 is propargyl or a propargyl containing moiety; wherein R7 is cyclohexylmethyl; wherein R8 is selected from n-propyl, isobutyl, cyclopropyl, cyclopropylmethyl, allyl and vinyl; and wherein each of R12 and R13 is a group independently selected from methyl, ethyl and isopropyl; or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: September 18, 2001
    Assignee: G. D. Searle & Co.
    Inventor: Gunnar J. Hanson